Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statistical models for low dose exposure

L Edler1, A Kopp-Schneider

  • 1Biostatistics Unit-R0700, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120, Heidelberg, Germany. edler@dkfz-heidelberg.de

Mutation Research
|September 28, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hybrid imaging with [<sup>68</sup>Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer.

Cancer imaging : the official publication of the International Cancer Imaging Society·2022
Same author

An R-shiny application to calculate optimal designs for single substance and interaction trials in dose response experiments.

Toxicology letters·2020
Same author

Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined <sup>18</sup>F-FDG and <sup>18</sup>F-FLT PET/CT imaging.

EJNMMI research·2018
Same author

<sup>68</sup>Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer.

European journal of nuclear medicine and molecular imaging·2018
Same author

Maximum intensity breast diffusion MRI for BI-RADS 4 lesions detected on X-ray mammography.

Clinical radiology·2017
Same author

Use of LDH and autoimmune side effects to predict response to ipilimumab treatment.

Immunotherapy·2016
Same journal

Monoallelic germline RAD51C, RAD51D, and BRIP1 variants in hereditary cancer testing: Variant spectrum and clinical counselling implications.

Mutation research·2026
Same journal

Prediction of hepatocellular carcinoma associated biomarkers in TP53 gene; A comprehensive in silico analysis.

Mutation research·2026
Same journal

IDH1 mutation promotes angiogenesis via upregulation of hypoxia inducible factor 1 alpha in glial tumors.

Mutation research·2026
Same journal

Targeting overexpressed oncogenes in esophageal cancer through miRNA-mediated gene silencing: Insights from binding affinity and thermodynamic profiling.

Mutation research·2026
Same journal

The active compound quercetin from Polygonum cuspidatum targets COL3A1 to enhance CD8⁺ T cell cytotoxicity in gastric cancer.

Mutation research·2026
Same journal

E2F1 promotes LIHC malignant phenotype via NEK2-mediated Wnt/β-catenin and Notch activation and EMT.

Mutation research·2026
See all related articles

Extrapolating health risks from high to low doses requires accurate dose-response models. This study reviews low-dose modeling, addressing threshold models and the Benchmark Dose concept for better carcinogenic risk assessment.

Area of Science:

  • Toxicology and risk assessment
  • Statistical modeling in biology
  • Carcinogenesis

Background:

  • Extrapolating health risks from high to low doses is crucial for carcinogenic risk assessment.
  • Current methods using high-dose data for low-dose predictions yield variable results, prompting calls for biologically informed models.
  • Toxicologists and risk modelers highlight the need for mechanistically-based stochastic modeling.

Purpose of the Study:

  • To summarize the current state of low-dose modeling in risk assessment.
  • To discuss controversial aspects of threshold models and the estimation of no observed adverse effect levels (NOAEL).
  • To present the Benchmark Dose (BMD) concept and its implications for mechanistic and statistical modeling.

Main Methods:

  • Review of statistical dose-response models used in high-to-low dose extrapolation.

Related Experiment Videos

  • Analysis of quantal and age/time-dependent tumor incidence models.
  • Consideration of biologically-based models like the multistage and two-stage clonal expansion models.
  • Examination of the relationship between administered and effective target doses.

    • Main Results:

    • Different dose-response models produce varying risk predictions at low doses.
    • Threshold models and NOAEL estimation remain subjects of debate in low-dose modeling.
    • Mechanistic models offer improved understanding but face identifiability challenges.
    • The Benchmark Dose concept provides a framework for risk assessment with consequences for modeling and estimation.

    Conclusions:

    • Accurate low-dose risk assessment necessitates mechanistically-informed dose-response models.
    • The Benchmark Dose concept offers a promising approach for integrating biological understanding into risk assessment.
    • Further research is needed to refine mechanistic models and address dose-response curve complexities.